DHA sbir phase I vacciraptor: high-throughput, continuous flow-through device for psoralen-UVA inactivation of dengue virus
Ended Purchase Order Awarded Last action
- Contract number
- HT942524P0078
- Awardee
-
Solaris Vaccines, Inc. UEI G1P5NEDCERA9
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $249,723
Award facts
- Contract value 100% obligated
- $249,723.49 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Fort Collins, CO 80521, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $249,723 |
About this award
The Defense Health Agency awarded a $249,723.49 firm fixed-price purchase order to Solaris Vaccines, Inc., a small biotechnology company based in Fort Collins, Colorado, on June 21, 2024. This Phase I Small Business Innovation Research (SBIR) contract, designated as a total small business set-aside, supports development of the VacciraRaptor technology—a high-throughput, continuous flow-through device designed to inactivate dengue virus using psoralen-UVA treatment. The contract is scheduled for completion by January 20, 2025, and represents an initial phase of innovation within the Department of Defense's broader vaccine development and infectious disease countermeasures portfolio.
Solaris Vaccines specializes in novel vaccine inactivation technologies utilizing photosensitizers and ultraviolet light to disrupt pathogen genetic material while maintaining antigenic integrity. This award follows the company's previous SBIR engagement with the Defense Health Agency and demonstrates continued investment in advanced vaccine development capabilities. The VacciraRaptor technology has potential applications for rapid, large-scale production of inactivated viral vaccines, addressing critical defense health priorities in pandemic preparedness and emerging infectious disease response.
Quick answers
Who was awarded contract HT942524P0078?
HT942524P0078 was awarded to Solaris Vaccines, Inc. by Defense Health Agency (Department of Defense) on June 21, 2024.
How much is contract HT942524P0078 worth?
The government has obligated $249,723 on HT942524P0078.
Was contract HT942524P0078 competed?
The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award